Segment reporting (Tables)

12 Months Ended

Jul. 31, 2019

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

The following financial information represents the operating results of the reportable segments of the Company:

Year ended July 31, 2019	Clinical Laboratory Services			Life Sciences Products			Therapeutics			Other			Consolidated
Revenues	$	51,115		$	30,055		$	—		$	—		$	81,170
Operating costs, expenses and legal settlements, net:
Cost of revenues		44,226			13,696			—			—			57,922
Research and development		31			2,257			887			—			3,175
Selling, general and administrative		24,230			11,860			—			8,175			44,265
Legal fee expense		159			27			—			2,814			3,000
Legal settlements, net		—			(28,925	)		—			—			(28,925	)
Total operating costs, expenses and legal settlements, net		68,646			(1,085	)		887			10,989			79,437
Operating income (loss)		(17,531	)		31,140			(887	)		(10,989	)		1,733
Other income (expense) Interest		(64	)		67			—			1,053			1,056
Other		16			2			—			364			382
Foreign exchange loss		—			(682	)		—			—			(682	)
Income (loss) before taxes	$	(17,579	)	$	30,527		$	(887	)	$	(9,572	)	$	2,489
Depreciation and amortization included above	$	1,625		$	1,221		$	—		$	190		$	3,036
Share-based compensation included above:
Selling, general and administrative		147			95			—		$	697			939
Total	$	147		$	95		$	—		$	697		$	939
Capital expenditures	$	1,374		$	605		$	—		$	6,147		$	8,126

Year ended July 31, 2018	Clinical Laboratory Services			Life Sciences Products			Therapeutics			Other			Consolidated
Revenues	$	71,077		$	29,936		$	—		$	—		$	101,013
Operating costs, expenses and legal settlements, net:
Cost of revenues		46,008			14,377			—			—			60,385
Research and development		—			2,305			905			—			3,210
Selling, general and administrative		24,656			11,617			—			8,182			44,455
Legal fee expense		67			58			—			5,002			5,127
Total operating costs, expenses and legal settlements, net		70,731			28,357			905			13,184			113,177
Operating income (loss)		346			1,579			(905	)		(13,184	)		(12,164	)
Other income (expense) Interest		(91	)		50			—			894			853
Other		29			11			—			128			168
Foreign exchange loss		—			(275	)		—			—			(275	)
Income (loss) before taxes	$	284		$	1,365		$	(905	)	$	(12,162	)	$	(11,418	)
Depreciation and amortization included above	$	1,667		$	1,387		$	—		$	76		$	3,130
Share-based compensation included in above:
Selling, general and administrative		125			79			—		$	609			813
Total	$	125		$	79		$	—		$	609		$	813
Capital expenditures	$	1,685		$	203		$	—		$	—		$	1,888

Year ended July 31, 2017	Clinical Laboratory Services			Life Sciences Products			Therapeutics			Other			Consolidated
Total revenues	$	74,689		$	30,397		$	—		$	—		$	105,086
Operating costs, expenses and legal settlements, net:
Cost of product revenues		45,400			14,078			—			—			59,478
Research and development		—			2,311			617			—			2,928
Selling, general and administrative		24,465			11,289			—			8,395			44,149
Legal fee expense		146			79			—			1,454			1,679
Total operating costs, expenses and legal settlements, net		70,011			27,757			617			9,849			108,234
Operating income (loss)		4,678			2,640			(617	)		(9,849	)		(3,148	)
Other income (expense)
Interest		(112	)		46			—			450			384
Other		137			(60	)		—			48			125
Foreign exchange gain		—			135			—			—			135
Income (loss) before taxes	$	4,703		$	2,761		$	(617	)	$	(9,351	)	$	(2,504	)
Depreciation and amortization included above	$	1,586		$	1,913		$	—		$	99		$	3,598
Share-based compensation included above:
Cost of clinical laboratory services	$	6		$	—		$	—		$	—		$	6
Selling, general and administrative		111			74			—		$	640			825
Total	$	117		$	74		$	—		$	640		$	831
Capital expenditures	$	1,363		$	390		$	—		$	—		$	1,753

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]

Geographic financial information is as follows:

Net sales to unaffiliated customers:	2019		2018		2017
United States	$	72,387	$	91,688	$	96,751
Switzerland		2,611		2,584		2,371
United Kingdom		1,611		1,851		1,673
Other international countries		4,561		4,890		4,291
Total	$	81,170	$	101,013	$	105,086

Long-lived assets at July 31,	2019		2018
United States	$	22,057	$	16,210
Switzerland		376		502
United Kingdom		64		127
Other international countries		96		135
Total	$	22,593	$	16,974

Schedule of Segment Revenue By Geographical [Table Text Block]

The following is a summary of the Life Sciences Products segment revenues attributable to customers located in the United States and foreign countries:

	2019		2018		2017
United States	$	21,272	$	20,610	$	22,062
Foreign countries		8,783		9,326		8,335
	$	30,055	$	29,936	$	30,397